| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01602185 | Neuropathic Pain | Drug: Dextromethorphan (drug used like antitussive)|Drug: Memantine (drug used in Alzheimer's disease)|Drug: Placebo (lactose) | University Hospital, Clermont-Ferrand|Dr Malou Navez, Pain Clinic, Saint-Etienne Hopital|Dr Marc Sorel, Pain Clinic, Nemours Hospital|Dr Anne-Margot Duclot, Pain Clinic, Paris Rotschild Hospital|Dr Monique Belon, Pain Clinic, Aurillac Hospital|Dr Marie-Christine Crosmary/Dr Renato Colamarino, Pain Clinic, Vichy Hospital|Dr Mohamed El Ayadi, Pain Clinic, Issoire Hospital|Dr G茅raldine Brumauld de Montgazon, Pain Clinic, La Rochelle Hospital | Phase 2 | 2012-05-01 | 2012-10-08 |
| NCT01553435 | Pain|Opioid Tolerance|Analgesia Tolerance | Drug: Dextromethorphan|Drug: Placebo | King Abdullah International Medical Research Center | | 2011-01-01 | 2015-04-12 |
| NCT00163059 | Depressive Disorder, Major | Drug: NMDA Antagonist, CP-101,606 (traxoprodil) | Pfizer | Phase 2 | 2004-05-01 | 2006-09-21 |
| NCT00163085 | Parkinson's Disease | Drug: NR2B NMDA Antagonist CP-101,606 (traxoprodil) | Pfizer | Phase 2 | 2005-05-01 | 2006-09-21 |
| NCT01474395 | Schizophrenia|Schizoaffective Disorder | Drug: D-serine|Drug: placebo|Behavioral: Sensory Based remediation paradigm | Nathan Kline Institute for Psychiatric Research|Columbia University | Phase 2 | 2012-03-01 | 2012-10-24 |
| NCT02950233 | Pain, Postoperative | Drug: NDMA|Drug: Steroid|Drug: NDMA Placebo|Drug: Steroid Placebo | Population Health Research Institute | Phase 3 | 2017-01-01 | 2016-10-31 |
| NCT00611897 | Cognitive Dysfunction | Drug: N-acetylcysteine and ketamine|Drug: placebo and ketamine | Yale University | Phase 1|Phase 2 | 2006-01-01 | 2015-05-07 |
| NCT01047592 | Schizophrenia | Drug: sarcosine|Drug: sarcosine+ BE|Drug: placebo | Chang-Hua Hospital|China Medical University Hospital | Phase 2 | 2009-03-01 | 2014-07-06 |
| NCT02994433 | Depressive Disorder, Major|Depressive Disorder, Treatment-Resistant | Drug: Nitrous Oxide|Drug: Placebo gas|Device: MRI | Washington University School of Medicine | Phase 1 | 2016-07-01 | 2016-12-14 |
| NCT02087202 | Pain | Drug: Magnesium Sulfate|Drug: ketamine | Seoul National University Bundang Hospital | | 2014-03-01 | 2014-03-12 |
| NCT00218465 | Nicotine Dependence | Drug: GW468816|Drug: Placebo Comparator: Placebo | Massachusetts General Hospital|National Institute on Drug Abuse (NIDA)|Mclean Hospital|GlaxoSmithKline | Phase 2 | 2006-08-01 | 2017-03-22 |
| NCT02675530 | Schizophrenia | Drug: ketamine | Yale University|AstraZeneca | Phase 1 | 2007-12-01 | 2016-02-04 |
| NCT00188383 | Hyperalgesia|Pain|Prostate Cancer | Drug: Amantadine | University Health Network, Toronto|Canadian Institutes of Health Research (CIHR) | Phase 1|Phase 2 | 2004-01-01 | 2006-03-13 |
| NCT00205712 | Psychoses, Substance-Induced | Drug: Ketamine|Drug: Dexmedetomidine | Washington University School of Medicine|National Alliance for Research on Schizophrenia and Depression | Phase 4 | 2003-02-01 | 2016-01-12 |
| NCT00364429 | Schizophrenia | Drug: [123]I-CNS 1261|Drug: Lorazepam|Drug: Risperidone | GlaxoSmithKline | Phase 1 | 2005-07-01 | 2016-01-07 |
| NCT01865578 | Anti-NMDA Receptor Encephalitis | Device: tDCS|Device: Sham Stimulation | Charite University, Berlin, Germany | | 2012-04-01 | 2016-03-16 |
| NCT02426983 | Schizophrenia | Device: Direct Current Stimulation|Drug: Dextromethorphan | University of Ottawa | Phase 1|Phase 2 | 2015-04-01 | 2015-04-21 |
| NCT01722578 | Cirrhosis of Liver|Hepatic Encephalopathy | Drug: L-ornithine L-aspartate|Drug: Placebo | Dayanand Medical College and Hospital | Phase 4 | 2013-12-01 | 2017-02-06 |
| NCT00338598 | Alcoholism|Schizophrenia | Drug: Glycine|Drug: placebo | Yale University|Stanley Medical Research Institute | Phase 2 | 2003-06-01 | 2016-07-11 |
| NCT02373124 | Cocaine Use Disorders | Drug: infusion of NMDA antagonist | New York State Psychiatric Institute | Phase 1|Phase 2 | 2014-12-01 | 2016-06-13 |
